-SEC Filing
Morgan Stanley Maintains Equal-Weight on Allakos, Lowers Price Target to $86
Morgan Stanley analyst Michael Ulz maintains Allakos (NASDAQ:ALLK) with a Equal-Weight and lowers the price target from $88 to $86.
Related Posts
RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $50
RBC Capital analyst Brian Abrahams maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Sector Perform and lowers the price target from $52 to $50.
Muscle Maker, Inc. Reports Top Line Revenue Over $58M For February 2023
Muscle Maker, Inc. (NASDAQ:GRIL), (the "Company"), today announced that it has achieved top line revenue of over $58 million for the month of February 2023. This revenue announcement marks the
